Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
2 - 4 μg/mL |
2.5 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Human Brain Tissue Slide(GTX22203) , Mouse Brain Tissue Lysate(GTX27934)
Product Note
This antibody does not cross-react with MANF.
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
CDNF antibody was raised against a 9 amino acid synthetic peptide from near the carboxy terminus of human CDNF.The immunogen is located within the last 50 amino acids of CDNF.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
cerebral dopamine neurotrophic factor , ARMETL1
Cellular Localization
Secreted
Background
The conserved dopamine neurotrophic factor (CDNF) is a neurotrophic factor for dopaminergic neurons and highly homologous to the mesencephalic-astrocyte-derived neuro-trophic factor. Somewhat surprisingly, CDCF is expressed at higher levels in tissues such as heart, skeletal muscle and testes than in brain. Similar to the glial cell line-derived neurotrophic factor (GDNF), CDNF can prevent the 6-hydroxylamine (6-OHDA)-induced degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. Furthermore, CDNF was able to restore the dopaminergic function and prevent the degeneration of dopaminergic neurons in the substantia nigra, suggesting that CDNF might be suitable for the treatment of Parkinson’s disease. At least two isoforms of CDNF are known to exist. This antibody does not cross-react with MANF.
Database
Research Area